<DOC>
	<DOCNO>NCT01165372</DOCNO>
	<brief_summary>Background : There worry sign Western Cambodia parasitological response artesunate contain treatment regimen uncomplicated falciparum malaria slow elsewhere world . Delayed parasite clearance unusually high failure rate artesunate-mefloquine report . These antimalarial central current treatment strategy spread significant resistance outside area would global disaster . Radical containment measure need . In context urgent need proceed quickly investigate whether evidence resistance artemisinin derivative Vietnam . Objective : The primary objective ass slope decline log parasitemia-time curve patient treat artesunate 2mg/kg/day , artesunate 4mg/kg/day dihydroartemisinin-piperaquine daily , compare result study pharmacokinetic result recent data patient Cambodia Thailand treat equivalent therapy . Methods : The trial conduct Phuoc Long Hospital , Binh Phuoc Province , Vietnam . The participant febrile patient ( age &gt; 10 year ) slide confirm uncomplicated P. falciparum infection . Patients treat either artesunate 2mg/kg/day , artesunate 4mg/kg/day dihydroartemisinin-piperaquine daily 3 day . Patients artesunate therapy arm receive 3 day treatment dihydroartemisinin-piperaquine dosage accord national guideline . Clinical parasitological parameter monitor 42-day follow-up period . The pharmacokinetic characteristic artesunate dihydroartemisinin assess use population pharmacokinetic modeling .</brief_summary>
	<brief_title>Study Malaria Treatment Phuoc Long Hospital , Binh Phuoc Province , Vietnam</brief_title>
	<detailed_description>This surveillance study three-arm prospective evaluation efficacy artesunate dihydroartemisinin-piperaquine acute uncomplicated falciparum malaria . This evaluation slope decline log parasitemia-time curve , parasite clearance time patient randomize one two different dos oral artesunate dihydroartemisinin-piperaquine . People uncomplicated malaria meet study inclusion criterion enrol , screen , randomize treat site either artesunate 2mg/kg/day , artesunate 4mg/kg/day dihydroartemisinin-piperaquine daily accord weight 3 day . The artesunate arm immediately follow dihydroartemisinin-piperaquine therapy 3 day ( study day 3 - 6 ) dose define national guideline . Patients three arm monitor 42 day . The follow-up consist fix schedule check-up visit correspond clinical laboratory examination . PCR analysis use distinguish true recrudescence due treatment failure reinfection .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>male age &gt; 10 year OR ; female patient &gt; 10 &lt; 12 year old , provide reach menarche monoinfection P. falciparum detect microscopy ; parasitaemia 10,000 100,000/µl asexual form ; presence axillary tympanic temperature ≥ 37.5 °C history fever past 24 h ; ability swallow oral medication ; ability willingness comply study protocol duration study comply study visit schedule ; inform consent/assent . presence general danger sign severe falciparum malaria accord definition WHO ; mixed monoinfection another Plasmodium specie detect microscopy ; presence severe malnutrition ( defined child whose growth standard 3 zscore , symmetrical oedema involve least foot midupper arm circumference &lt; 110 mm ) ; presence febrile condition due disease malaria ( e.g . measles , acute low respiratory tract infection , severe diarrhoea dehydration ) know underlie chronic severe disease ( e.g . cardiac , renal hepatic disease , HIV/AIDS ) ; regular medication , may interfere antimalarial pharmacokinetics ; treatment antimalarial drug previous 48 hour ; history hypersensitivity reaction contraindication medicine ( ) test used alternative treatment ( ) ; splenectomy .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Drug resistance</keyword>
</DOC>